临床试验/NCT07218003

NCT07218003Enrolling By Invitation1 期

An Open-Label, Multicenter, Phase 1/1b Study of RNDO-564 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer and Other Solid Tumors Associated With Nectin-4 Expression

Rondo Therapeutics11 个研究点分布在 1 个国家目标入组 149 人开始时间: 2025年11月17日最近更新: 2026年6月11日

适应症

干预措施

试验速览

阶段: 1 期
状态: Enrolling By Invitation
发起方
入组人数: 149
试验地点: 11
主要终点: All Arms: - Proportion of participants with adverse events (including dose limiting toxicities) as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab. The study is focused on participants with certain solid tumors that are in an advanced stage and have certain tumor makers. This will be done by measuring the side effects that participants experience and how severe they are. Additionally, the study will evaluate how RNDO-564 moves into, through, and out of the body and how the treatment affects the body.

The second goal of this study is to evaluate how well RNDO-564 works by itself or in combination with pembrolizumab at treating participants' cancer. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured.

Participants will take RNDO-564 weekly on Days 1, 8 and 15 of a 21 day cycle. Participants in the combination arms will take RNDO-564 as described with pembrolizumab every 3 weeks.

详细描述

The study will consist of four stages: 1) single agent dose escalation, 2) single agent dose optimization, 3) combination dose escalation and 4) combination dose optimization.

Stages 1 and 3 are dose escalation to investigate the safety and tolerability of increasing doses of RNDO-564 as a single agent and in combination with standard pembrolizumab treatment. Participants will be enrolled who have one of the following advanced solid tumors associated with Nectin-4: locally advanced/metastatic urothelial cancer (la/m UC), cervical cancer (CC), head and neck cancer (HNSCC), esophageal cancer (EC), gastric (GC) and gastroesophageal junction cancer (GEJ), triple negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC). The cancer must not have responded well to previous cancer treatments. Stages 1, and 3 will be non-randomized.

Stages 2 (i.e., RNDO-564 single agent) and 4 (i.e., RNDO-564 in combination with pembrolizumab) are dose optimization and proof-of-concept stages to further investigate the safety and tolerability of at least 2 doses of RNDO-564 as a single agent and in combination with standard pembrolizumab treatment, and to investigate preliminary anti-tumor activity. Stages 2 and 4 will enroll participants with advanced urothelial cancer only. The cancer must not have responded well to previous cancer treatments. Participants will be randomized (1:1) into one of two arms which will evaluate two dose levels (as selected from Stages 1 and 3).

The study consists of a screening period, a treatment period, an end of treatment visit, a safety follow-up visit, and 60 and 90 days telephone follow-up after ending treatment. The treatment period will last for a maximum of 2 years.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Sequential
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•1) Eligible tumor types: Histologic documentation of incurable, locally advanced or metastatic solid tumors for which established standard systemic therapies are no longer effective (participant must have experienced progressive disease), are not tolerated, or in the opinion of the Investigator have been considered ineligible for a particular form of standard therapy on medical grounds or have been declined by the participant, with these tumor subtypes:
•A. Monotherapy and Combination Dose Escalation Arms:
•RR la/mUC: Participants with urothelial cancer (transitional cell) with squamous differentiation or mixed cell types are eligible. Participants with upper tract disease, e.g., involving ureters, or renal pelvis, are eligible. Participants may have had up to 2 prior monomethyl auristatin E (MMAE)-containing therapies, assuming any existing peripheral neuropathy is Grade 2 or less.
•GC and GEJ
•B. Dose Optimization (Monotherapy and Combination Arms):
•Limited to participants who have RR la/mUC,
•Participants may have had up to 2 prior MMAE-containing therapies, assuming any existing peripheral neuropathy is Grade 2 or less
•Participants must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.
•3. Adequate organ function

排除标准

•For Nectin-4 targeted agents (approved or investigational)
•> one prior Nectin-4 targeted agents
•Peripheral neuropathy > Grade 2
•Participants with a history of, or with active, inflammatory skin disease, such as eczema, psoriasis that required or currently require biologics or oral steroids to control disease are ineligible.

干预措施: RNDO-564 (Drug)

Combination Dose Escalation- Dose Level 1

Experimental

Combination Dose Escalation- Dose Level 1

干预措施: RNDO-564 (Drug)

结局指标

主要结局

All Arms: - Proportion of participants with adverse events (including dose limiting toxicities) as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

时间窗: From Day 1 to 90-days post last dose

• Type, frequency, and severity of adverse events (AEs)

Dose Optimization Arms: • Identify one or more recommended Phase 2 doses (RP2D)

时间窗: From Day 1 up to 24 months

To evaluate the totality of data

次要结局

All Arms: To evaluate serum concentrations at specified timepoints of RNDO-564 as a single agent or in combination with pembrolizumab(From Day 1 up to 25 months (inclusive of 30 day safety follow-up))
All Arms: Proportion of participants that develop anti-drug antibodies to RNDO-564(Baseline (predose) up to 25 months (inclusive of 30 day safety follow-up))
All Arms: Duration of Response(Time between the first partial response or complete response and the date of first documented progression or date of death, whichever came first, assessed up to 24 months)
All Arms: Evaluate the prevalence, incidence and impact of anti-drug antibodies to RNDO-564(From Baseline (predose) up to 25 months (inclusive of the 30 day safety follow-up).)
All Arms: Objective Response Rate Among Participants(percentage of participants from Day 1 until the date of the first documented partial response or complete response assessed up to 24 months)
All Arms: Median Progression Free Survival Time Among Participants(The number of months from Day 1 until the date of first documented progression or date of death, whichever came first, assessed up to 24 months)

研究者

发起方

Rondo Therapeutics

申办方类型

Industry

责任方

Sponsor

研究点 (11)

Loading locations...

相似试验

已完成

2 期

Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian CancerEpithelial Ovarian Cancer

NCT00408603Sunesis Pharmaceuticals183

已完成

1 期

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult ParticipantsHealthy VolunteersBirch Pollen Allergy

NCT03969849Regeneron Pharmaceuticals96

终止

1 期

A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid TumorsSolid Tumors

NCT04158583Hoffmann-La Roche76

终止

1 期

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)Ulcerative Colitis

NCT03943550Hoffmann-La Roche45

已完成

1 期

Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.OsteopeniaBone DiseaseOsteoporosis

NCT01293487Pfizer68